Astra Zeneca and blood clot risk in Europe

Health Canada has issued the following advisory statement “ Health Canada is aware of reports of adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine, and would like to reassure Canadians that the benefits of the vaccine continue to outweigh its risks. Health Canada authorized the vaccine based on a thorough, independent review of the evidence and determined that it meets Canada’s stringent safety, efficacy and quality requirements.”

Thrombosis Canada has stated that, based on the available evidence, there is no link between receiving this vaccine and the development of blood clots. Thrombosis Canada strongly recommends the administration of the COVID-19 vaccines, including in people who have had a previous blood clot, in people with a family member who has had a blood clot, and in people who are receiving a blood thinning treatment. More information is available at: statement-on-astrazeneca-covid-19-vaccine-and- thrombosis/